VANDA PHARMACEUTICALS Releases FY2023 Q2 Earnings Report for June 30 2023

August 25, 2023

🌥️Earnings Overview

On July 27 2023, VANDA PHARMACEUTICALS ($NASDAQ:VNDA) reported their earnings from FY2023 Q2 ending June 30 2023. Their total revenue was USD 46.1 million, a 28.5% decrease from the same quarter last year, and their net income was USD 1.5 million; 40.9% lower than the same quarter in the previous year.

Market Price

VANDA PHARMACEUTICALS attributed the decrease in revenue to a decline in global demand for its products, as well as increasing competition from other pharmaceutical companies. However, the company plans to continue investing in research and development to stay competitive and remain profitable in the future. With their continued focus on research and development, they should be able to remain competitive and provide long-term growth to shareholders. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Vanda Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    238.35 14.9 6.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Vanda Pharmaceuticals. More…

    Operations Investing Financing
    40.84 50.05 0.61
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Vanda Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    641.68 101.78 9.39
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Vanda Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -0.3% -26.2% 4.1%
    FCF Margin ROE ROA
    16.9% 1.1% 0.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an analysis of VANDA PHARMACEUTICALS‘s fundamentals. After our assessment, we can confidently rate VANDA PHARMACEUTICALS as a medium risk investment in terms of financial and business aspects. More specifically, our risk assessment discovered two areas of concern that should be taken into account when considering an investment in VANDA PHARMACEUTICALS. Namely, we observed potential issues with the company’s income sheet and cashflow statement. If you are interested in the details of our analysis and the risk warnings that we identified, we encourage you to register with us. With a quick sign up process, you can gain access to our detailed report and learn more about how we rate VANDA PHARMACEUTICALS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Vanda’s lead product is Fanapt, which is approved in the United States and Canada for the treatment of schizophrenia. Vanda has a portfolio of other products in various stages of development. The company’s competitors include Zogenix Inc, Akeso Inc, and Atea Pharmaceuticals Inc.

    – Zogenix Inc ($SEHK:09926)

    Akeso Inc is a global biopharmaceutical company that develops and commercializes innovative therapies. The company has a market cap of 26.07B as of 2022 and a Return on Equity of -32.08%. Akeso Inc’s products are designed to treat a wide range of diseases, including cancer, infectious diseases, and autoimmune disorders. The company’s most recent product is a treatment for advanced solid tumors.

    – Akeso Inc ($NASDAQ:AVIR)

    Atea Pharmaceuticals Inc is a pharmaceutical company with a market cap of 442.94M as of 2022. The company has a return on equity of 2.2%. Atea Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of novel treatments for serious or life-threatening diseases. The company’s lead product candidates are AT-001 for the treatment of patients with severe sepsis or septic shock, and AT-002 for the treatment of patients with acute myocardial infarction (heart attack).


    VANDA PHARMACEUTICALS recently reported their Q2 FY2023 earnings on July 27, 2023. Total revenue decreased 28.5% year over year to USD 46.1 million, while net income fell 40.9% to USD 1.5 million. This news may cause investors to take a more cautious stance when considering an investment in VANDA PHARMACEUTICALS.

    Although the company has achieved positive results in past quarters, the sustained decrease in revenues and income suggests that there may be larger underlying issues facing the company that could impact their future performance. Investors should be aware of these potential risks when evaluating VANDA PHARMACEUTICALS as an investment opportunity.

    Recent Posts

    Leave a Comment